Evidence map›Paper›PMID 36841811›Full record

ArticleCell death discovery2023

MiR-130a-3p regulates FUNDC1-mediated mitophagy by targeting GJA1 in myocardial ischemia/reperfusion injury.

Yan Yan, Liu-Yang Tian, Qian Jia, Yang Han, Yu Tian, Hui-Ning Chen, Sai-Jia Cui, Jie Xi, Yong-Ming Yao, Xiao-Jing Zhao

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Mitophagy in cardiovascular diseases: a literature review.Cardiovascular diagnosis and therapy · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yan Yan *Medical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Liu-Yang Tian *School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Qian JiaMedical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Yang HanMedical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Yu TianMedical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Hui-Ning ChenMedical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Sai-Jia CuiMedical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Jie XiMedical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Yong-Ming YaoMedical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China. c_ff@sina.com.ORCID http://orcid.org/0000-0002-3564-4012
Xiao-Jing ZhaoMedical Innovation Research Division, the Chinese PLA General Hospital, Beijing, 100853, People's Republic of China. xjingzhao@126.com.ORCID http://orcid.org/0000-0002-4937-9088
Chinese PLA General Hospital · CNNankai University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82001994National Natural Science Foundation of China (National Science Foundation of China) 82130062
6 · The paper itself

Abstract

Understanding the complex pathogenesis in myocardial ischemia/reperfusion (I/R) injury (IRI) is an urgent problem in clinical trials. Increasing pieces of evidence have suggested that miRNAs are involved in the occurrence and development of heart diseases by regulating mitochondria-related gene expression. Mitochondria have been acknowledged as the key triggers of cardiac I/R injury. However, the potential impact of miR-130a on mitochondria remains unclear in myocardial IRI. Exploring the regulatory mechanism of miR-130a on mitochondria may provide a new target for IRI therapy. In the present study, we found that miR-130a significantly increased in acute myocardial infarction (AMI) patients and myocardial I/R rats. MiR-130a could downregulate the viability of cardiomyocytes and the knockdown of miR-130a could protect the viability of cardiomyocytes under hypoxia-reoxygenation (HR). Over-expression of miR-130a resulted in mitochondrial dysfunction. It was evidenced by decreases in mitochondrial ATP production, mitochondrial membrane potential (MMP), and an increase in reactive oxygen species (ROS) production. However, suppression of miR-130a could protect against mitochondrial damage, show elevation of mitochondrial ATP production rate and MMP, and reduce ROS production. We further explored the effect of miR-130a on the mitochondrial quality control (QMC) system by determining mitochondrial-protein-specific proteases and analyzed mitochondrial morphology by fluorescence imaging and electron microscopy, respectively. It was noted that miR-130a could suppress mitochondrial fusion and FUNDC1-mediated mitophagy to accelerate myocardial IRI. Moreover, we investigated the potential miR-130a targeted mitochondria-related genes to understand the regulatory mechanism of miR-130a in the setting of myocardial IRI. It was revealed that miR-130a targeted GJA1, and GJA1 rescued IRI by enhancing ATP production rate and oxidative phosphorylation, meanwhile protecting cell viability, MMP, and activating mitophagy. In addition, the knockdown of miR-130a significantly activated FUNDC1-mediated mitophagy, while the knockdown of GJA1 reversed the relevant response. Collectively, our findings suggest that miR-130a regulates FUNDC1-mediated mitophagy by targeting GJA1 in myocardial IRI.

Identifiers

PMID36841811
PMCPMC9968299
OpenAlexW4322009188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.